TL;DR
This study uses network pharmacology to unravel the molecular mechanisms behind Jinhong decoction (JHD), a traditional Chinese medicine, in treating sepsis and COVID-19. By identifying shared molecular targets and pathways, the research suggests JHD acts through a multi-pronged approach, offering a promising therapeutic strategy for these co-occurring, life-threatening conditions.
What Problem Does This Paper Address?
Sepsis and COVID-19 are devastating diseases that often occur together, exacerbating each other's severity and leading to significantly higher mortality rates. While Jinhong decoction (JHD) has shown clinical promise in treating these conditions, its underlying molecular mechanisms remain largely unknown. This lack of understanding hinders the optimization and broader application of JHD. The paper aims to bridge this knowledge gap by employing network pharmacology to dissect the complex interactions between JHD's active components, their molecular targets, and the shared pathological pathways of sepsis and COVID-19.
Methods
The researchers employed a multi-faceted network pharmacology approach. This involved:
- Active Ingredient and Target Identification: They screened JHD's components and their potential molecular targets using established databases like TCMSP, HERB, PubChem, and SwissTargetPrediction. Specific criteria for oral bioavailability (OB ≥ 30%) and drug-likeness (DL ≥ 0.18) were applied to filter for effective ingredients.
- Disease Target Identification: Targets associated with sepsis and COVID-19 were gathered from multiple disease databases, including DisGeNET, OMIM, Drugbank, TTD, and GeneCards.
- Network Construction: The identified drug targets and disease targets were intersected to find common targets. These common targets were then used to construct a protein-protein interaction (PPI) network using the STRING database and visualized with Cytoscape.
- Core Target and Pathway Analysis: Topological analysis of the PPI network was performed to identify key therapeutic targets. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were conducted using the DAVID database to pinpoint significant biological pathways and molecular functions involved in JHD's therapeutic action.
- Transcriptomic Data Analysis: Publicly available gene expression profiles from sepsis and COVID-19 patient datasets (GEO database) were analyzed to validate the differential expression of the identified key target genes. Tissue and cell distribution of these key targets were also investigated using the BioGPS platform.
Datasets
The study utilized several publicly available databases for its analysis:
- Drug Databases: TCMSP, HERB, PubChem.
- Disease Databases: DisGeNET, OMIM, Drugbank, TTD, GeneCards.
- Protein-Protein Interaction Database: STRING.
- Gene Expression Datasets: GEO database (specifically GSE95233 for sepsis and GSE171110 for COVID-19).
- Tissue Distribution Database: BioGPS.
No new datasets or benchmarks were introduced in this study.
Key Insights and Ideas
- "Homotherapy for Heteropathy" in Action: The study provides a molecular basis for the traditional Chinese medicine principle of "homotherapy for heteropathy" (treating different diseases with similar pathogenesis using the same therapy). It demonstrates how JHD can target shared molecular mechanisms in both sepsis and COVID-19.
- Multi-Target, Multi-Pathway Synergy: JHD doesn't act on a single target or pathway. Instead, it orchestrates a complex interplay of multiple ingredients targeting multiple genes and modulating several key signaling pathways, highlighting its broad-spectrum therapeutic potential.
- Key Players Identified: The identification of six core target genes (AKT1, MMP9, ICAM1, TLR4, BCL2, and HIF1A) provides specific molecular nodes for understanding JHD's action and potential therapeutic interventions.
- Immune and Inflammatory Regulation is Central: The identified targets and pathways are heavily involved in regulating immunometabolism, inflammation, and cell survival, which are critical processes dysregulated in both sepsis and COVID-19.
- Targeting Specific Cell Types: The tissue distribution analysis points to CD33+ myeloid cells, fetal lung cells, and bronchial epithelial cells as crucial sites of action for JHD's therapeutic effects, offering insights into where the drug's impact is most significant.
Key Results
- 54 Shared Targets: The study identified 54 common molecular targets between JHD and the diseases of sepsis and COVID-19.
- Six Core Therapeutic Targets: Through PPI network analysis, six key target genes were identified: AKT1, MMP9, ICAM1, TLR4, BCL2, and HIF1A.
- Ten Key Signaling Pathways: GO and KEGG enrichment analyses revealed ten significantly enriched signaling pathways involved in the treatment of sepsis and COVID-19 by JHD, including the HIF-1, TNF, and NF-κB signaling pathways.
- Differential Gene Expression: Transcriptomic analysis confirmed that the expression patterns of the six key target genes were altered in sepsis and COVID-19 patients compared to healthy controls, validating their involvement in these diseases. For instance, MMP9, ICAM1, and TLR4 showed significantly higher expression in both disease groups, while AKT1 and BCL2 showed lower expression in sepsis.
- Tissue Distribution Insights: CD33+ myeloid cells, fetal lung cells, and bronchial epithelial cells were identified as having the highest expression of the key target genes, suggesting their importance in JHD's therapeutic action.
Limitations and Future Work
The authors acknowledge several limitations:
- Dataset Integration Bias: Combining data from multiple databases might introduce redundancy and potential biases. The authors mitigated this by implementing deduplication steps.
- Computational Reliance: The findings are primarily based on database predictions and computational simulations.
- Oversimplification of Complexity: Network pharmacology might oversimplify the complex biological interactions of JHD, potentially leading to an overestimation of drug-likeness and a neglect of off-target effects.
Future work should focus on:
- Experimental Validation: Conducting animal and clinical experiments is crucial to validate the proposed mechanisms and therapeutic efficacy of JHD.
- Broader Applications: Exploring the potential of JHD for treating other related diseases based on its identified mechanisms.
Summary updated